Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening – The VICTORION-PLAQUE primary prevention trial

By afschroeder • August 7, 2025

Revaiah PC, Serruys PW, Onuma Y, Andreini D, Budoff MJ, Sharif F, Chernofsky A, Vikarunnessa S, Wiethoff AJ, Yates D, Achouba A. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTORION-PLAQUE primary prevention trial. Am Heart J. 2025 Aug 4:S0002-8703(25)00291-1. doi: 10.1016/j.ahj.2025.08.001. Epub ahead of print. PMID: 40769373.

Tags: Cardiology/Epi, CCTA derived Fractional Flow Reserve (FFR(CT)), coronary computed tomography angiography (CCTA), CT-adapted Leaman score, Harbor UCLA, Inclisiran, Low density Lipoprotein Cholesterol (LDL-C), non-obstructive coronary artery disease (NOCAD), Publications, total atheroma volume (TAV)

Association of Ramus intermedius with increased atherosclerotic plaque in the left main stem

Pourafkari L, Ansari S, Kinninger A, Budoff MJ. Association of Ramus intermedius with increased atherosclerotic plaque in the left main stem. Int J Cardiovasc Imaging.[...]

Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial

DeVore AD, Majmudar M, Etters L, Xie J, Hao C, Lam PH, Hernandez AF, Fonarow GC, Desai AS. Digital Platform to Optimize Guideline-Directed Heart Failure[...]

Trinuclear Heptamethine Dyes for Shortwave Infrared In Vivo Imaging

Garcia CA, Lin EY, Mobley EB, Louie A, Hartung KM, Araujo JA, Sletten EM. Trinuclear Heptamethine Dyes for Shortwave Infrared In Vivo Imaging. Angew Chem[...]